# Total Neoadjuvant Therapy in Rectal Cancer

Source: https://onco.cc/trials/nct06162650/  
OnCo record `nct06162650` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by National Cheng-Kung University Hospital, now recruiting.

## Summary

Total Neoadjuvant Therapy in Rectal Cancer is a phase 2, interventional study registered as NCT06162650 by National Cheng-Kung University Hospital, with a registry enrolment figure of 42 participants, started 2023-11-16 and due to reach its primary completion in 2026-11-16. Interventions recorded: Short-course radiotherapy; mFOLFOX6. Conditions listed: Rectal Cancer. Primary outcome: Complete response (CR) rate. Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of adenocarcinoma of the rectum;". Sites: Taiwan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06162650
- Phase: 2
- Setting: A Phase II Study of Total Neoadjuvant Therapy in Rectal Cancer
- Sponsor: National Cheng-Kung University Hospital
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT06162650: https://clinicaltrials.gov/study/NCT06162650

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06162650.json